SC 13G/A: Stoke Therapeutics, Inc.
Ticker: STOK · Form: SC 13G/A · Filed: Feb 26, 2024 · CIK: 1623526
| Field | Detail |
|---|---|
| Company | Stoke Therapeutics, Inc. (STOK) |
| Form Type | SC 13G/A |
| Filed Date | Feb 26, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by Stoke Therapeutics, Inc..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G/A filing submitted by Stoke Therapeutics, Inc. (ticker: STOK) to the SEC on Feb 26, 2024.
What is the risk level of this SC 13G/A filing?
This filing has been assessed as low risk.
How long is this filing?
Stoke Therapeutics, Inc.'s SC 13G/A filing is 3 pages with approximately 912 words. Estimated reading time is 4 minutes.
Where can I view the full SC 13G/A filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 912 words · 4 min read · ~3 pages · Grade level 8.2 · Accepted 2024-02-26 10:38:58
Filing Documents
- stoka1_22624.htm (SC 13G/A) — 25KB
- 0001085146-24-001540.txt ( ) — 27KB
(a)
ITEM 1(a). NAME OF ISSUER: Stoke Therapeutics, Inc.
(b)
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 3 Preston Ct. Bedford, MA 01730
(a)
ITEM 2(a). NAME OF PERSON FILING: Cowen Financial Products LLC
(b)
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: 599 Lexington Ave. New York, NY 10022
(c)
ITEM 2(c). CITIZENSHIP: Delaware
(d)
ITEM 2(d). TITLE OF CLASS OF SECURITIES: Common Stock
(e)
ITEM 2(e). CUSIP NUMBER: 86150R107 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c); (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8); (e) [ ] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution: ITEM 4. (a) Amount beneficially owned: 3,721,659 (b) Percent of class: 8.3% (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: Cowen Financial Products LLC : 3,721,659 (ii) shared power to vote or to direct the vote: Cowen Financial Products LLC : (iii) sole power to dispose or direct the disposition of: Cowen Financial Products LLC : 3,721,659 (iv) shared power to dispose or to direct the disposition of: Cowen Financial Products LLC : ITEM 5. If this statement is being filed to report the fact that as of the dat